Halozyme Therapeutics | HALO - 资产



金融业
股票价格
USD
资产
USD 2.67B
现金及等价物
USD 309.75M
销售成本
USD 108.75M
流动资产
USD 1B
流动负债
USD 363.21M
债务
USD 2.14B
EBIT
USD -61.77M
EBITDA
USD 219.57M
员工
350
EPS每股收益
USD 1.6
股本和储备
USD 219.64M
销售毛利
USD 297.47M
债务利息支出
USD 5.51M
贷款资金
USD 1.94B
市值
USD 8.56B
净收入
USD 150.05M
营业费用
USD 192.19M
营业利润
USD -61.77M
普通股股本
USD 118.52M
PE价格收益
11.35
税前利润
USD 180.33M
销售收入
USD 377M
销售和管理费用
USD 46.29M
股票
USD 155.47M
贸易债权人
USD 14.1M
应收帐款人
USD 457.99M


资产 更改 日
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amarin USD 645.76M 25.01M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Baxter International USD 19.85B 209M 2026-03
Cara Therapeutics USD 32.07M 6.95M 2025-12
Cytokinetics USD 1.27B 151.06M 2026-03
DBV Technologies USD 233.72M 123.22M 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
Esperion Therapeutics USD 462.53M 3.36M 2026-03
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Intrexon USD 73.16M 77.88M 2024-06
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
MannKind USD 744.4M 47.78M 2026-03
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Pfizer USD 207.62B 542M 2026-03
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
United Therapeutics USD 6.71B 1.17B 2026-03
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12